Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if oral treatment with ONO-2506PO in patients
diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization,
could lead to the slowing of decline in respiratory function, functional status, muscle
strength, quality of life and survival compared with placebo group.